FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

 

Report of Foreign Issuer

 

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
 


For period ending November 2009
 

GlaxoSmithKline plc
(Name of registrant)
 
 

 

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
 
 

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
 
 

Form 20-F x Form 40-F
 

 --

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
 
 
Yes No x
  --

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.
 

Date: 18 November 2009
 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2009

To:

30 October 2009

Balance of unallotted securities under scheme(s) from previous return:

5,295,707

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

268,191

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

5,027,516


Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000


  
 
 

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.
 

Date: 18 November 2009
 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Share Option Plan - ADS

Period of return:

From:

1 May 2009

To:

31 October 2009

Balance of unallotted securities under scheme(s) from previous return:

6,389,424

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

363,648

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

6,025,776


Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000


  
 
 

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.
 

Date: 18 November 2009
 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

Glaxo Wellcome UK Share Option Scheme

Period of return:

From:

1 May 2009

To:

31 October 2009

Balance of unallotted securities under scheme(s) from previous return:

5,119,750

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

5,119,750


Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000


  
 
 

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.
 

Date: 18 November 2009
 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

Glaxo Wellcome International Share Option Scheme

Period of return:

From:

1 May 2009

To:

31 October 2009

Balance of unallotted securities under scheme(s) from previous return:

13,267,156

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

13,267,156


Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000


  
 
 
 

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.
 

Date: 18 November 2009
 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

Glaxo Wellcome 1999 Share Option Plan

Period of return:

From:

1 May 2009

To:

31 October 2009

Balance of unallotted securities under scheme(s) from previous return:

1,040,000

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1,040,000


Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000


  
 
 

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.
 

Date: 18 November 2009
 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

SmithKline Beecham 1989 Executive Share Option Plan - Approved - Ordinary Shares

Period of return:

From:

1 May 2009

To:

31 October 2009

Balance of unallotted securities under scheme(s) from previous return:

163,606

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

163,606


Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000


  
 
 

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.
 

Date: 18 November 2009
 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS

Period of return:

From:

1 May 2009

To:

31 October 2009

Balance of unallotted securities under scheme(s) from previous return:

275,420

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

275,420


Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000


  
 
 

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.
 

Date: 18 November 2009
 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - Ordinary

Period of return:

From:

1 May 2009

To:

31 October 2009

Balance of unallotted securities under scheme(s) from previous return:

100,000

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

100,000


Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000


  
 
 

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.
 

Date: 18 November 2009
 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline Savings Related Share Option Scheme

Period of return:

From:

1 May 2009

To:

31 October 2009

Balance of unallotted securities under scheme(s) from previous return:

5,264,981

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

73,735

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

5,191,246


Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
 
 

GlaxoSmithKline plc
(Registrant)
 
 

Date: November 18, 2009

By: VICTORIA WHYTE

------------------

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc